LBTD (Lotus Bio-Technology Development) EBIT: $-0.01 Mil (TTM As of Dec. 2017)


What is Lotus Bio-Technology Development EBIT?

Lotus Bio-Technology Development LBTD -99.99% EBIT is $-0.01 Mil as of Dec. 2017.

Lotus Bio-Technology Development's earnings before interest and taxes (EBIT) for the three months ended in Dec. 2017 was $-0.00 Mil. Its earnings before interest and taxes (EBIT) for the trailing twelve months (TTM) ended in Dec. 2017 was $-0.01 Mil.

EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition. Lotus Bio-Technology Development's annualized ROC % for the quarter that ended in Dec. 2017 was -80.00%. Lotus Bio-Technology Development's annualized ROC (Joel Greenblatt) % for the quarter that ended in Dec. 2017 was -80.00%.

EBIT is also linked to Joel Greenblatt's definition of earnings yield.

Lotus Bio-Technology Development  (OTCPK:LBTD) EBIT Explanation

1. EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition.

Lotus Bio-Technology Development's annualized ROC % for the quarter that ended in Dec. 2017 is calculated as:

ROC % (Q: Dec. 2017 )
=NOPAT/Average Invested Capital
=Operating Income * ( 1 - Tax Rate % )/( (Invested Capital (Q: Sep. 2017 ) + Invested Capital (Q: Dec. 2017 ))/ count )
=-0.004 * ( 1 - 0% )/( (0 + 0.005)/ 1 )
=-0.004/0.005
=-80.00 %

where

Invested Capital(Q: Sep. 2017 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=0 - 0 - ( 0 - max(0, 0 - 0+0))
=0

Invested Capital(Q: Dec. 2017 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=0.055 - 0.067 - ( 0.05 - max(0, 0.067 - 0.05+0.05))
=0.005

Note: The Operating Income data used here is four times the quarterly (Dec. 2017) data.

2. Joel Greenblatt's definition of Return on Capital:

Lotus Bio-Technology Development's annualized ROC (Joel Greenblatt) % for the quarter that ended in Dec. 2017 is calculated as:

ROC (Joel Greenblatt) %(Q: Dec. 2017 )
=EBIT/Average of (Net fixed Assets + Net Working Capital)
=EBIT/Average of (Property, Plant and Equipment+Net Working Capital)
     Q: Sep. 2017  Q: Dec. 2017
=EBIT/( ( (Property, Plant and Equipment + Net Working Capital) + (Property, Plant and Equipment + Net Working Capital) )/ count )
=-0.004/( ( (0 + max(0, 0)) + (0.005 + max(-0.067, 0)) )/ 1 )
=-0.004/( ( 0 + 0.005 )/ 1 )
=-0.004/0.005
=-80.00 %

where Working Capital is:

Working Capital(Q: Sep. 2017 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(0 + 0 + 0) - (0 + 0 + 0)
=0

Working Capital(Q: Dec. 2017 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(0 + 0 + 0) - (0.067 + 0 + 0)
=-0.067

When net working capital is negative, 0 is used.

Note: The EBIT data used here is four times the quarterly (Dec. 2017) EBIT data.

3. It is also linked to Joel Greenblatt's definition of Earnings Yield:

Lotus Bio-Technology Development's Earnings Yield (Joel Greenblatt) % for today is calculated as:

Earnings Yield (Joel Greenblatt) %=EBIT (TTM)/Enterprise Value (Q: Dec. 2017 )
=-0.013/0.000
= %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Lotus Bio-Technology Development EBIT Related Terms

Lotus Bio-Technology Development EBIT Historical Data

* Premium members only.

The historical data trend for Lotus Bio-Technology Development's EBIT can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Lotus Bio-Technology Development EBIT Chart

Lotus Bio-Technology Development Annual Data
Trend Mar11 Mar12 Mar13 Mar14 Mar15 Mar16 Mar17
EBIT
Get a 7-Day Free Trial -0.06 -0.02 -0.02 -0.78 -0.02

Lotus Bio-Technology Development Quarterly Data
Mar13 Jun13 Sep13 Dec13 Mar14 Jun14 Sep14 Dec14 Mar15 Jun15 Sep15 Dec15 Mar16 Jun16 Sep16 Dec16 Mar17 Jun17 Sep17 Dec17
EBIT Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -0.02 0.00 0.00 -0.02 -0.00

LBTD vs SNES, CVAT: EBIT Comparison

For the Agricultural Inputs subindustry, Lotus Bio-Technology Development's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Lotus Bio-Technology Development EV-to-EBIT vs Agriculture Industry

For the Agriculture industry and Basic Materials sector, Lotus Bio-Technology Development's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where Lotus Bio-Technology Development's EV-to-EBIT falls into.


Lotus Bio-Technology Development EBIT Calculation

EBIT, sometimes also called Earnings Before Interest and Taxes, is a measure of a firm's profit that includes all expenses except interest and income tax expenses. It is the difference between operating revenues and operating expenses. When a firm does not have non-operating income, then Operating Income is sometimes used as a synonym for EBIT and operating profit.

EBIT for the trailing twelve months (TTM) ended in Dec. 2017 adds up the quarterly data reported by the company within the most recent 12 months, which was $-0.01 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about EBIT →
What does a EBIT of $-0.01 Mil mean?
Lotus Bio-Technology Development (LBTD) has a EBIT of $-0.01 Mil as of Dec. 2017. Earnings before interest and taxes is the difference between operating revenue and operating expenses. View historical data on Lotus Bio-Technology Development.
Is Lotus Bio-Technology Development's EBIT too high?
Lotus Bio-Technology Development's current EBIT is $-0.01 Mil.
How does Lotus Bio-Technology Development's EBIT compare to SNES and CVAT?
Lotus Bio-Technology Development's EBIT of $-0.01 Mil can be compared against companies in the Agriculture industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBIT for an Agriculture company?
A good EBIT depends on the Agriculture industry context. However, EBIT should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBIT mean?
A high EBIT can signal that a stock is expensive relative to its fundamentals. Earnings before interest and taxes is the difference between operating revenue and operating expenses. View historical data on Lotus Bio-Technology Development. Lotus Bio-Technology Development's current EBIT is $-0.01 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Lotus Bio-Technology Development stock overvalued right now?
Lotus Bio-Technology Development (LBTD) has a current EBIT of $-0.01 Mil. The current EBIT is $-0.01 Mil. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBIT calculated?
EBIT is calculated from a company's financial statements. For Lotus Bio-Technology Development (LBTD), the current EBIT is $-0.01 Mil as of Dec. 2017. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Lotus Bio-Technology Development Business Description

Address 108 2559 Parkview Lane, Port Coquitlam, BC, CAN, V3C6M1
Lotus Bio-Technology Development Corp is actively seeking out new opportunities in the Organic and Bio-technology space.